Koselugo, a new drug for pediatric neurofibroma, is once again awaiting discussion for listing on insurance benefits. Attention is focused on whether AstraZeneca Korea's neurofibromatosis new drug Koselugo, which was decided for re-discussion at HIRA last month, will be presented to the committee on the 7th. Koselugo failed to reach an agreement at the committee last month even though the pharmaceutical company submitted supplementary data and a risk-sharing plan.

This disease begins in childhood with milk-coffee spots measuring 1 to 3 cm. Afterward, they experience symptoms such as optic nerve glioma (brain tumor) around the age of 6 and scoliosis between the ages of 6 and 10. In adults, Lisch nodules